Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
PAMIDRONATE DISODIUM
PHARMASCIENCE INC
M05BA03
PAMIDRONIC ACID
15MG
POWDER FOR SOLUTION
PAMIDRONATE DISODIUM 15MG
INTRAVENOUS
100
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0123608007; AHFS:
APPROVED
2004-01-27
PRODUCT MONOGRAPH PR PMS-PAMIDRONATE (Pamidronate disodium for injection, House standard) 15mg/vial, 30 mg/vial, 60 mg/vial and 90 mg/vial For intravenous infusion only BONE METABOLISM REGULATOR PHARMASCIENCE INC DATE OF REVISION: 6111 Royalmount Ave., Suite 100 March 30, 2017 Montreal, Quebec H4P 2T4 www.pharmascience.com CONTROL NO. 200445 _pms-PAMIDRONATE Product Monograph _ _Page 2 of 44_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS....................................................................................... 4 ADVERSE REACTIONS....................................................................................................... 10 DRUG INTERACTIONS ....................................................................................................... 14 DOSAGE AND ADMINISTRATION ................................................................................... 15 OVERDOSAGE ..................................................................................................................... 20 ACTION AND CLINICAL PHARMACOLOGY ................................................................. 20 STORAGE AND STABILITY............................................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 25 PART II: SCIENTIFIC INFORMATION ................................................................................ 26 PHARMACEUTICAL INFORMATION............................................................................... 26 CLINICAL TRIALS .................... Կարդացեք ամբողջական փաստաթուղթը